Volkswagen's excess emissions will lead to 1,200 premature deaths in Europe

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide between 2008 and 2015. The devices were designed to detect and adapt to laboratory tests, making the cars appear to comply with environmental standards when, in fact, they emitted pollutants called nitric oxides, or NOx, at levels that were on average four times the applicable European test-stand limit.

While Volkswagen has issued recalls of affected vehicles in both the U.S. and Europe, scientists at MIT and elsewhere have found the excess emissions has already had an impact on public health. The team previously estimated that the excess emissions generated by 482,000 affected vehicles sold in the U.S. will cause approximately 60 premature deaths across the U.S.

Now the researchers have looked closer to Volkswagen's home base, examining the health impact from the 2.6 million affected cars sold in Germany under Volkswagen Group's brands VW, Audi, Skoda, and Seat. In a paper published today in Environmental Research Letters, the team reports that the manufacturer's emissions in excess of the test-stand limit value have had a significant effect on public health not just in Germany but across Europe.

The researchers estimate that 1,200 people in Europe will die early, each losing as much as a decade of their life, as a result of excess emissions generated between 2008 and 2015 by affected cars sold in Germany. Of these premature deaths, 500 will likely occur in Germany, meaning that more than 60 percent of premature mortalities stemming from those German-sold cars will occur in neighboring countries, most notably Poland, France, and the Czech Republic.

"Air pollution is very much transboundary," says co-author Steven Barrett, the Leonardo-Finmeccanica Associate Professor of Aeronautics and Astronautics at MIT. "[Pollution] doesn't care about political boundaries; it just goes straight past. Thus, a car in Germany can easily have significant impacts in neighboring countries, especially in densely populated areas such as the European continent."

If Volkswagen can recall and retrofit affected vehicles to meet European standards by the end of 2017, this would avert 2,600 additional premature deaths, or 29,000 life years lost, and 4.1 billion Euros in corresponding health costs, which would otherwise be expected in the absence of a recall.

Barrett's co-authors from MIT are lead author and graduate student Guillaume Chossière, postdoc Akshay Ashok, research assistant Irene Dedoussi, and research scientist Raymond Speth. Sebastian Eastham of Harvard University and Robert Malina of Hasselt University in Belgium are also co-authors.

Something in the air
Barrett says that it's not surprising that Germany, and Europe as a whole, incur higher health impacts from Volkswagen's excess emissions, as compared to the U.S. Not only were more affected cars sold in Germany (2.6 million) than in the U.S. (482,000), differences in population density, driving behavior, and atmospheric conditions also help explain the aggravated health impacts across Europe.

For instance, Europe's average population density is about three times higher than the U.S. average, and historical data has shown that diesel cars in Germany are driven on average 20 percent more, in terms of annual mileage, compared to the average American car that was considered in the U.S. study. In other words, there are more affected cars on the road, generating emissions that affect a higher concentration of people.

Atmospheric conditions play a role, as well. NOx is emitted from the engine as a gas, which can be carried by winds over long distances before or while reacting with ammonia in the air to form fine particulates. Since the atmosphere in Europe happens to contain more ammonia than in the U.S., more fine particulates may form from a given amount of NOx. It is exposure to these fine particulates which has been shown to cause cardiopulmonary and respiratory disease. NOx emissions also contribute to the formation of ozone, another pollutant known to be detrimental to human health.

"It takes time for NOx to get converted into particulates, at which point, they could be 100 to 200 kilometers or further away from their source," Barrett says.

Excess emissions' health effects
The researchers arrived at their mortality estimates using a method similar to the one they adopted to assess Volkswagen's health impacts in the U.S. The team based their analysis in part on the German Federal Motor Transport Authority's measurements of emissions from Volkswagen cars.

They then used historical data on driving behavior in Germany to estimate the number of kilometers driven by each car per year and where drivers were likely to drive the most. From that, the researchers generated a map of excess emissions within Germany.

Barrett and his colleagues worked this emissions map into a simulation of the atmosphere, modeling where the NOx emissions traveled, given prevailing winds, temperature, and precipitation, and where the gas interacted with other compounds to form fine particulates and ozone.

The atmospheric models produced a map of fine particulates and a map of ozone, which the team then overlaid on population density maps across Europe. With these maps, they calculated people's exposure to Germany-derived excess emissions, for each country in the European Union. From these exposure estimates, the researchers calculated the increased risk of dying early in the population, using a "concentration response function" - a relationship between a person's exposure to a given dose of a pollutant and the person's related health risk.

"It ends up being about a one percent extra risk of dying early in a given year, per microgram per meter cubed of fine particles you're exposed to," Barrett says. "Typically that means that someone who dies early from air pollution ends up dying about a decade early."

Volkswagen and beyond
Overall, the researchers found that 1,200 premature deaths will likely occur as a result of excess emissions that have already been released into the atmosphere between 2008 and 2015. Of these, 500 early deaths occur in Germany, followed by 160 in Poland, 84 in France, and 72 in the Czech Republic, with the remainder split among other European countries.

The researchers performed the same analysis a second time, under a scenario in which Volkswagen fixes affected cars to meet regulatory standards by the end of 2017, generating no excess emissions starting in January 2018. Under this scenario, the company would avert 2,600 premature deaths, or 29,000 years of life lost.

Going forward, the researchers plan to expand their study of auto emissions' health impact, concentrating on diesel vehicles in Europe.

"It seems unlikely that Volkswagen is the only company with issues with excess emissions," Barrett says. "We don't know if other manufacturers have these defeat devices, but there is already evidence that many other vehicles in practice emit more than the applicable test-stand limit value. So we're trying to do this for all diesel vehicles."

Guillaume P Chossière, Robert Malina, Akshay Ashok, Irene C Dedoussi, Sebastian D Eastham, Raymond L Speth, Steven R H Barrett.
Public health impacts of excess NOx emissions from Volkswagen diesel passenger vehicles in Germany.
Environ. Res. Lett. 12 (2017) 034014, http://iopscience.iop.org/1748-9326/12/3/034014

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

Towards a safe and scalable cell therapy for type …

More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune sys...

Read more

XELJANZ® (tofacitinib citrate) receives marketing …

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination wi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]